Back to search

University of Crete (UOC)

Ο ρόλος της Ιρινοτεκάνης (CPT-11) στη θεραπευτική αντιμετώπιση του μεταστατικού καρκίνου του παχέος εντέρου

Abstract

dc:description

Colorectal cancer (CRC) represents 10% of all new cancer cases and is the third most common neoplasm in men and the second in women. The median overall survival (OS) of metastatic CRC (mCRC) without any treatment is approximately 6 months. For decades the treatment of choice was the combination of 5FU/LV, with a modest clinical benefit. The introduction of new agents (irinotecan, oxaliplatin, bevacizumab, cetuximab, panitumuimab) has increased OS from 12 to over 22 months. Irinotecan, a water soluble analogue of camptothecin, is active in mCRC. 70% of all cases of CRC is diagnosed over the age of 65 years old and almost 40% over 75, with a median age of diagnosis of 71. Available data indicate that fewer elderly patients are treated with the newer agents compared to younger patients. Due to the small number of older patients that participate in clinical trials, data concerning the safety and efficacy of chemotherapy are sparse and they are mainly derived from subgroup analyses and pooled analyses of randomized phase 3 trials. The aim of this dissertation is to examine the optimal use of irinotecan in the management of mCRC (combination with fluropyrimidines, efficacy and safety of irinotecan combinations in patients over 65 years old). Sequential phase I, II and III studies were conducted in order to define the optimal way to administer irinotecan in mCRC and to combine it with fluoropyrimidines. An analysis of the patients >65 years from the two randomized trials compared the efficacy and safety of irinotecan in elderly patients compared to younger ones. Treatment naïve patients were enrolled in the studies. In the phase I trial, the MTD level for 5-FU was found to be 600 mg/m2/day days 1-4 and for CPT-11 350 mg/m2 in day 4. Dose limiting toxicities were neutropenic fever, neutropenia, diarrhea and mucositis, with an overall response rate (ORR) 22%. The phase II trial of the FOLFIRI combination showed that it is an active and safe regimen is mCRC. The ORR was 45%, median time to progression (TTP) 8 months, 1-year OS rate 63.5% and the serious adverse events were neutropenia 36%, neutropenic fever 7%, diarrhea 13% and mucositis 6%. The phase III trial of the FOLFOXIRI regimen versus FOLFIRI was the first randomized study to examine the activity of the combination of all the active drugs for CRC (5-FU, oxaliplatin, irinotecan). There was no statistically significant difference in OS (21.5 vs 19.5 months, p=0.337), TTP (8.4 vs 6.9 months, p=0.17) and RR (43% vs 33.6%, p=0.168). Patients enrolled in the FOLFOXIRI arm had statistically significant higher rates of alopecia (p=0.0001), diarrhea (p=0.001) and neurotoxicity (p=0.001); toxic deaths were similar. Dose reductions and delays in chemotherapy administration were more frequent in the FOLFOXIRI arm and dose intensities were lower. In the randomized phase II trial of the combination of FOLFIRI/bavacizumab versus CAPIRI/bevacizumab, there were no differences in progression free survival (PFS, 10 vs 8.9 months, p=0.85), median OS (25.7 vs 27.5 months, p=0.30) and ORR (45.5% vs 39.8%, p=0.32). However, patients treated in the CAPIRI/bevacizumab arm experienced higher rates of grade 3/4 neutropenic fever (p<0.001), diarrhea (p=0.003) and hand foot syndrome (p=0.003), more chemotherapy delays (p=0.05), dose reductions (p<0.001) and treatment discontinuations due to toxicity (p=0.01). In the analysis of the two randomized trials (609 patients), 52.7% of the patients were >65 years old. There was no correlation between treatment efficacy and age. TTP (8.9 vs 8.4 months, p=0.76), median OS (25 vs 22 months, p=0.214) and 1-year survival rates (72% vs 73.7%) were similar. In the contrary, ORR was higher among younger patients (45.5% vs 34.9%, p=0.008). There were higher death rates among older patients from other causes apart from cancer-related and toxiv deaths (8% vs 1.3%, p=0.018). Serious diarrhea was more frequent in elderly patients that received FOLFIRI or FOLFOXIRI (p=0.005 and p=0.017 respectively), whereas older patients that were treated with FOLFOXIRI and CAPIRI/bevacizumab had diarrhea more frequently compared to those that received FOLFIRI with or without bevacizumab. Regarding the addition of bevacizumab, it does not seem to increase the rates of adverse events in older patients compared to younger ones. Out of the 8 toxic deaths, 7 occurred in elderly patients. In conclusion, the above data define irinotecan as an important component of the treatment of mCRC. Intensive irinotecan-containing regimens should be carefully administered to younger patients who are candidates for metastasectomy. Older patients can be treated with itinotecan-based combinations but not with intensive regimens. FOLFIRI is a reasonable choice for first line treatment in mCRC in elderly patients. CAPIRI should be avoided in this age group due to toxicity-related concerns. Adding bevacizumab to FOLFIRI in patients over 65 years old with mCRC is also a reasonable choice.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Vamvakas, Lampros
  • Βαμβακάς, Λάμπρος

Subjects

dc:subject × 6

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/34895

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Vamvakas, Lampros; Βαμβακάς, Λάμπρος. Ο ρόλος της Ιρινοτεκάνης (CPT-11) στη θεραπευτική αντιμετώπιση του μεταστατικού καρκίνου του παχέος εντέρου. University of Crete (UOC), 2014. http://hdl.handle.net/10442/hedi/34895